Gaba A Receptor Beta 1 Subunit plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Gaba A Receptor Beta 1 Subunit is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gaba A Receptor Beta 1 Subunit plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Gaba A Receptor Beta 1 Subunit is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GABRB1 encodes the beta 1 subunit of the GABA-A receptor, a critical component of the major inhibitory neurotransmitter receptor in the brain. GABA-A receptors are pentameric chloride channels that mediate fast inhibitory neurotransmission throughout the central nervous system. These receptors are the primary targets for benzodiazepines, barbiturates, and general anesthetics, making them among the most clinically important neurotransmitter receptors[@supsup2006].
Gene Overview
Official Symbol: GABRB1
Official Name: Gamma-Aminobutyric Acid Type A Receptor Beta1 Subunit
Chromosomal Location: 4q12
NCBI Gene ID: 2565
UniProt ID: P18505
OMIM: 137192
Gene Family: Cys-loop ligand-gated ion channel family
Protein Structure and Function
The GABRB1 protein (485 amino acids) forms the beta subunit of the GABA-A receptor:
Structural Features
N-terminal Extracellular Domain: Contains the ligand binding site for GABA, benzodiazepines, and other modulators
Transmembrane Domain: Four transmembrane helices (M1-M4) forming the chloride channel pore
Intracellular Loop: Between M3 and M4, contains phosphorylation sites
C-terminal Domain: Important for subunit assembly and trafficking
Receptor Assembly
Pentameric Assembly: GABA-A receptors are typically composed of 2 alpha, 2 beta, and 1 gamma (or delta) subunits
Stoichiometry: Most common is α1β2γ2 or α2β3γ2
Alternative Subunits: Can incorporate α4, α5, α6, β3, γ1, γ3, δ, π, ε subunits
Gating Mechanism
GABA Binding: Two GABA molecules bind at α-β interfaces
GABRB1 Knockout Mice: Show increased anxiety, seizures, altered sleep architecture, and reduced GABA sensitivity
Transgenic Models: Overexpression studies reveal region-specific effects on behavior
Point Mutation Studies: Specific mutations alter channel gating and pharmacology
Key Publications
[@supsup2006] E. R. S. Macdonald, "GABA_A receptors: structure and function," Current Topics in Medicinal Chemistry, vol. 3, no. 8, pp. 855-869, 2003. PMID: 12678842(https://pubmed.ncbi.nlm.nih.gov/12678842/)
[@supsup2017] L. B. K. Rissman, "GABAergic dysfunction in Alzheimer's disease," Journal of Alzheimer's Disease, vol. 33, no. 3, pp. 781-792, 2013. PMID: 23099815(https://pubmed.ncbi.nlm.nih.gov/23099815/)
[@supsup2013] R. W. M. Olsen, "GABA_A receptor pharmacology," Biochemical Pharmacology, vol. 68, no. 6, pp. 1065-1078, 2004. PMID: 15313388(https://pubmed.ncbi.nlm.nih.gov/15313388/)
Overview
Gaba A Receptor Beta 1 Subunit plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Gaba A Receptor Beta 1 Subunit has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Unknown, <sup>[1]</sup> P. J. Whiting, "GABA-A receptors: a viable target for novel anxiolytics?," Current Opinion in Pharmacology, vol. 6, no. 1, pp. 30-36, 2006 (2006)](https://pubmed.ncbi.nlm.nih.gov/16368264/))
[<sup>[2]</sup> R. L. Li et al., "GABAergic system dysfunction in Alzheimer's disease," Journal of Alzheimer's Disease, vol. 57, no. 3, pp. 785-797, 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28269758/))
[<sup>[3]</sup> M. S. Scarr et al., "GABA-A receptor subunit expression in temporal lobe epilepsy," Epilepsia, vol. 54, no. 8, pp. 1374-1382, 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/23730814/))
[<sup>[4]</sup> J. M. Dekker et al., "GABAergic dysfunction in the pathogenesis of epilepsy in Alzheimer's disease," Neurobiology of Disease, vol. 139, p. 104814, 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32028011/))
[<sup>[5]</sup> K. A. Saliba et al., "GABRB1 mutations and epilepsy," Brain, vol. 135, pt. 7, pp. 2027-2038, 2012 (2027)](https://pubmed.ncbi.nlm.nih.gov/22719071/))